Development of full human monoclonal Ab to human TRAIL-Rs for tumor therapy / 实用肿瘤学杂志
Practical Oncology Journal
; (6): 344-348, 2014.
Article
em Zh
| WPRIM
| ID: wpr-499217
Biblioteca responsável:
WPRO
ABSTRACT
Monoclonal antibodies(mAbs)to human TRAIL receptors(TRAIL-Rs)have been developed in tumor targeted therapy and currently used in clinical Ⅰ~Ⅳtrials.MAbs can bind death-receptors(TRAIL-R1 and TRAIL-R2)and then results in formation of the death inducing signaling complex (DISC)and apoptosis of tumor cells.TRAIL -Rs mAbs have become one of the research and development hotspots of anti -tumor drugs.These mAbs have achieved remarkable results in combination with radio -or chemo-therapy drugs or oth-er agents and immunotherapy in the treatment of tumor and offer a new therapeutic strategy for clinical tumor treatment.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Practical Oncology Journal
Ano de publicação:
2014
Tipo de documento:
Article